Hong Kong Pharma Digital Technology Holdings Ltd
HKPDDrugs in Pipeline
15
Phase 3 Programs
4
Upcoming Catalysts
3
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
3 upcoming, 0 past
metformin
Polycystic Ovary Syndrome
prednisolone and mycophenolate mofetil
Lupus Nephritis
Conventional medication
Parkinson Disease
prednisolone and chlorambucil
Glomerulonephritis, Membranous
AEG35156 antisense IV infusion
Advanced Hepatocellular Carcinoma
EI-001
Non-segmental Vitiligo
pegylated recombinant human arginase
Hepatocellular Carcinoma
Umbilical Cord Blood Mononuclear Cell
Spinal Cord Injuries
20-herb formulation
Irritable Bowel Syndrome
EGCG and Quinine Sulfate Vaginal Suppository
High-risk HPV (Any Strain)
Natural killer cell
Neuroblastoma Recurrent
PACOX
Hepatocellular Carcinoma
INS018_055
Idiopathic Pulmonary Fibrosis (IPF)
ISM3412
Locally Advanced/Metastatic Solid Tumors
Pegylated Recombinant Human Arginase I
Neoplasm
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
metformin | Phase 3 | Polycystic Ovary Syndrome | - | - |
prednisolone and mycophenolate mofetil | Phase 3 | Lupus Nephritis | - | - |
Conventional medication | Phase 3 | Parkinson Disease | - | - |
prednisolone and chlorambucil | Phase 3 | Glomerulonephritis, Membranous | - | - |
AEG35156 antisense IV infusion | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
EI-001 | Phase 2 | Non-segmental Vitiligo | - | - |
pegylated recombinant human arginase | Phase 2 | Hepatocellular Carcinoma | - | - |
Umbilical Cord Blood Mononuclear Cell | Phase 2 | Spinal Cord Injuries | - | - |
20-herb formulation | Phase 2 | Irritable Bowel Syndrome | - | - |
EGCG and Quinine Sulfate Vaginal Suppository | Phase 2 | High-risk HPV (Any Strain) | - | - |
Natural killer cell | Phase 2 | Neuroblastoma Recurrent | - | - |
PACOX | Phase 2 | Hepatocellular Carcinoma | - | - |
INS018_055 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | - | - |
ISM3412 | Phase 2 | Locally Advanced/Metastatic Solid Tumors | - | - |
Pegylated Recombinant Human Arginase I | Phase 2 | Neoplasm | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Hong Kong Pharma Digital Technology Holdings Ltd's drug pipeline?→
CatalystAlert tracks 15 drug candidates in Hong Kong Pharma Digital Technology Holdings Ltd's (HKPD) pipeline across Phase 3, Phase 2. Its lead program is metformin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Hong Kong Pharma Digital Technology Holdings Ltd's next FDA catalyst?→
Hong Kong Pharma Digital Technology Holdings Ltd's (HKPD) next tracked catalyst is a Phase 2 expected December 27, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HKPD biotech catalysts?→
Add HKPD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Hong Kong Pharma Digital Technology Holdings Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.